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Background: Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal neoplasia in
the gastrointestinal tract, although they represent only a small fraction of total gastrointestinal malignancies in
adults (<2%). GISTs can be located at any level of the gastrointestinal tract; the stomach is the most common
location (60-70%), in contrast to the rectum, which is most rare (4%). When a GIST invades into the adjacent
prostate tissue, it can simulate prostate cancer. In this study, we report on a case comprising the unexpected
collision between a rectal GIST tumour and a prostatic adenocarcinoma.
Findings: We describe the complexity of the clinical, endoscopic and radiological diagnosis, of the differential
diagnosis based on tumour biopsy, and of the role of neoadjuvant therapy using imatinib prior to surgical
treatment.
Conclusions: Although isolated cases of coexisting GISTs and prostatic adenocarcinomas have previously been
described, this is the first reported case in the medical literature of a collision tumour involving a rectal GIST and
prostatic adenocarcinoma components.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1238437468776331.
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The term gastrointestinal stromal tumor (GIST) was
first introduced in 1983 by Mazur and Clark as a neutral
term between smooth muscle tumours and schwanno-
mas. GIST is currently used to refer to a heterogeneous
group of mesenchymal tumour lesions, acquired or con-
genital, with common morphological profiles that usu-
ally settle within the digestive tract.
Although GISTs are the most common primary mes-
enchymal tumours of the gastrointestinal tract (70%),
they represent only a small fraction of all gastrointestinal
malignancies in adults (<2%).* Correspondence: laura.macias.garcia@gmail.com
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reproduction in any medium, provided the orGISTs usually affect adults between 6th and 8th dec-
ades of life without specific gender prevalence (M:F,
1.1:1) [1]. Its annual incidence rates range from 6.8 and
14.5 cases per million in the U.S. States and in Sweden,
respectively [2]. GISTs include benign and malignant
neoplasia that immunohistochemically stain positively
for KIT (CD117) and that phenotypically differentiate
into cells of Cajal. The histological (e.g., cellularity
spindle and/or epithelioid) and immunohistochemical
(e.g., CD117 and CD34 immunostaining) profiles allow
for simple morphological diagnosis.
In 1998, Hirota et al. showed that the majority of
GISTs exhibit activating mutations in the KIT protoon-
cogene. Subsequently, in 2003, a new mutation in
PDGFRA and the sensitivity of GISTs to tyrosine kinase
inhibitors such as imatinib were demonstrated. These
findings represent an important advance in the clinicalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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this tumour [2]. Although the mutations in KIT and
PDGFRA represent the basis of GIST oncogenesis,
5-10% of the GIST cases are negative for mutations in
KIT [3].
GISTs can be located at any level of the gastrointes-
tinal tract. The stomach is the most common location
(60-70%), whereas rectal GIST represents only 4% of all
GISTs [1]. When these tumours invade into the prostate,
they can clinically simulate a prostatic adenocarcinoma
[4]. The direct invasion of the prostate by a rectal GIST
is rare [4-7] and the case presented in our study involves
an added diagnostic complexity: a collision tumour in-
volving both histological types of neoplasia. The combin-
ation of a rectal GIST that invades into the prostate and
a primary prostatic adenocarcinoma in a collision
tumour has never before been described in the medical
literature.Figure 1 A: Rectal GIST: Excrescent and ulcerated rectal mass
with stenosis of the rectal lumen. B: Rectal GIST with prostatic
infiltration: rectal tumour with direct invasion of both adjacent
lobules of the prostate. UB: urinary bladder; ADC: prostatic
adenocarcinoma; AC: Anal canal; R: rectum; P: prostate.Materials and methods
Case presentation
The patient examined in this study was a 52-year-old
male with no relevant personal or family history of dis-
ease, who presented with rectal tenesmus, rectal bleed-
ing, and obstructive urinary symptoms. A digital rectal
exam revealed a fixed submucosal mass in the anterior
rectal wall, attached to the prostate and located 2–3 cm
from the anal margin. The prostate specific antigen
(PSA) value was 3.16 mg/ml, with a pathologic PSA ratio
of 0.0937. Rectoscopic and echo-endoscopic evaluations
revealed a rectal neoplasia with prostatic infiltration.
A computed tomography (CT) scan performed at 5
months prior to the surgical intervention revealed a re-
latively well-defined heterogeneous mass of 60 mm ×
36 mm × 45 mm affecting the anterior wall of the rectum
in contact with the prostate, with effacement of the fat
separating the two organs.
Magnetic resonance imaging (MRI) performed at the
same time revealed a large (7–8 cm) tumour in the distal
rectum, affecting the adjacent prostate and causing sten-
osis of the rectal lumen. The CT scan and the MRI
results both revealed an absence of metastasis in the
local and distant lymph nodes.
A biopsy of the tumour revealed a profile that was
consistent with a mesenchymal neoplasia of uncertain
malignancy that was positive for CD117 (cytoplasmic
and membranous staining), the expression of which is
characteristic of GISTs.
The treatment protocol consisted of neoadjuvant treat-
ment with imatinib abdominoperineal rectal amputation
with a radical cystectomy and prostatectomy. A pre-
operative CT scan demonstrated an apparent reduction
in the tumour size, measuring 50 mm × 30 mm, wherethe separation between the rectum and prostate was dif-
ficult to delineate.
Pathologic evaluation
Grossly, the surgical specimen was an excrescent mass
located within the anterior rectal wall that exhibited a 7-
cm maximum diameter and focally ulcerated mucosa
(Figure 1: A). An incision revealed a fleshy appearance
with haemorrhagic foci and infiltration into of over half
of both lobes of the prostate (Figure 1: B). Histologically,
we observed spindle tumour cells with moderate atypia
that were arranged in a fascicular pattern, as well as ex-
tensive haemorrhagic areas without relevant necrotic
foci (Figure 2). The mitotic index was 18/50 high-power
field (HPF). We observed no other regressive changes at-
tributable to treatment with imatinib, except for the
haemorrhagic foci. The immunohistochemical profile of
the spindle cell tumour was as follows: cytoplasmic and
membrane CD117+, CD34+ (Figure 3: A, B), vimentin+,
actin HHF-35-, actin SMA-, desmin-, and S-100-, and a
Ki-67 proliferative index of 15%.
The prostate tissue adjacent to the infiltrative front of
the spindle cell tumour exhibited diffuse proliferation of
microglandules and well-defined cribriform structures
with focal intraluminal mucin secretion and atypical
cells with prominent nucleoli (Figure 4).
Histopathological diagnosis identified the collision
tumour involving a high-risk GIST of the spindle cell
variant that originated in the anterior rectal wall and
that exhibited perirectal extension and wide infiltration
of the adjacent peripheral prostate lobules, as well as a
prostatic acinar adenocarcinoma with a combined Glea-
son score of 6 (3+3) and confined involvement to the left
and right prostate lobules (pT2c). The seminal vesicles
and urinary bladder exhibited no evidence of neoplasia.
Figure 2 Rectal GIST: Spindle cell tumour with haemorrhagic
foci. HE (100x).
Figure 4 Collision tumour rectal GIST/prostatic
adenocarcinoma. HE (50x).
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and neoadjuvant treatment with imatinib, the patient is
asymptomatic and cancer-free.
Discussion
GIST is the most common type of non-epithelial neopla-
sia diagnosed in the gastrointestinal tract (0.1-3% of all
gastrointestinal tumours) with an incidence rate of 10–
20 cases per million population [8]. However, these
tumours rarely occur in the rectum; the reported inci-
dence rate is approximately 1 case per 1000 GISTs [7].
The presentation of these tumours can range from
asymptomatic nodules smaller than 1 cm that are inci-
dentally diagnosed in the surgical specimens of rectalFigure 3 A, B: Rectal GIST: Positive immunostaining with CD117
(cytoplasmic and membranous) and CD34.resections to masses larger than 10 cm (“giant GISTs”)
that result in altered intestinal function, rectal bleeding
in the case of ulceration, abdominal pain, and urinary
symptoms attributed to bladder compression [9]. When
located in the anterior wall of the rectum in male
patients, such tumours might cause difficulties in urin-
ation along with pelvic and perineal pain, producing
symptoms similar to prostatism. In rare cases, the
tumour can extend into the prostate gland, clinically and
radiologically simulating prostate cancer [4]. Histologi-
cally, rectal GISTs tend to contain large spindle tumour
cells that are often arranged in palisades.
The immunohistochemical profile of the tumour was
similar to gastric GISTs. As many as 90-100% of tumour
cells exhibited strong immunopositivity for CD117,
DOG-1, and CD34 and were generally immunonegative
for SMA and S-100. These tumours behave in an aggres-
sive fashion, exhibiting a high rate of recurrence, pelvic
extension, and hepatic and bone metastases [1].
The differential diagnosis of rectal GIST with prostatic
involvement in the biopsy specimens is primarily based
on immunohistochemical evaluation and includes differ-
ent stromal neoplasias with spindle cell patterns that
can affect the rectum and prostate. These tumours in-
clude primarily smooth muscle tumours (leiomyomas,
leiomyosarcomas), schwannomas, fibromatosis, a solitary
fibrous tumour and a malignant melanoma. The differ-
ential histological and immunological characteristics of
the tumours localised in this region are summarised in
(Table 1).
To confirm the diagnosis of a GIST, a KIT or
PDGFRA mutational analysis can be performed, al-
though this was not a possible option in our patient.
GIST is known to coexist with certain neoplasias, in-
cluding pulmonary chondromas and paragangliomas
(Carney’s triad). For the diagnostic of CT (Carney´s




















































































Rarely positive Negative Sometimes focal Very rare Positive Negative
Actina (SMA) Sometimes
positive
Positive Positive Negative Positive Rarely Negative
Desmina Rarely Positive Positive Negative Very rare Negative Negative
S-100 Rarely Very rare Very rare Strongly positive Negative Negative Positive
HMB-45 Negative Negative Negative Negative Negative Negative Positive
Beta-Catenin Negative Negative Negative Negative Positive Negative Negative
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association of GIST and pulmonary chondroma is the
most common combination [10]. Sporadic GISTs of the
adults are completely different from CT-GISTs and
pediatric GISTs. Regional lymph nodes are frequently
metastasize by both GISTs (29%), while their occurrence
in common GISTs seen in adults is rare (2%) [10]. Fur-
thermore, multiple types of GISTs have been associated
with type I neurofibromatosis.
However, these cases have been described as syn-
chronous or metachronous association between sporadic
GISTs and other neoplasia [11,12], with a mean second-
ary tumour incidence rate of 9.3%, according to the data
from 15 different previous studies including 4,777 GIST
patients [13], and up to 13.8% according to data from a
recent study [14]. The majority of secondary tumours
described were gastrointestinal adenocarcinomas, al-
though a large study also reported a relative 9% inci-
dence of prostatic adenocarcinoma [11].
Radical cystoprostatectomy performed due to bladder
carcinoma showed prostatic acinar adenocarcinoma in the
49.6% of the cases [15], where 81.3% of these cases repre-
sented clinically insignificant prostatic adenocarcinomas.However, in this study, the prostatic tumour was extensive
and multifocal, with peripheral affectation of the prostate
lobules and exhibiting a relevant Gleason score (3 + 3).
The tumour exhibited no apparent contacts with the sur-
gical margins and no extraprostatic extensions. However,
in the regions of collision with the rectal GIST, it was not
possible to determine the precise extent of the tumour.
Rectal GISTs are rare tumours, whereas prostatic
adenocarcinoma is the most prevalent type of non-
cutaneous neoplasia in elderly men. On this basis, rectal
and prostate tumours are generally initially considered
as prostatic adenocarcinomas or prostatic infiltrations
of rectal adenocarcinomas. Only 6 cases have been
described of prostatic infiltration by rectal GISTs [4-7],
all of which were initially diagnosed as primary prostatic
leiomyosarcomas by evaluation of transrectal biopsy.
Surprisingly, GISTs have also been described as a type of
primary prostatic tumour [16]. In all cases, the final
diagnosis is established by analysing the surgical speci-
men. In our study, the collision of two histologically dis-
tinct tumour types increased the complexity of the
clinical, radiological, and histological diagnosis. This is
the first case describing a collision tumour involving
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adenocarcinoma. This pathological situation greatly con-
founded the clinical diagnosis, particularly given the
presence of a rectal mass, rectal and prostatic symptoms,
and pathological levels of PSA.
Until recently, the treatment of giant rectal GISTs has
been limited to surgical resection, except for cases of in-
operable tumours or metastases that contraindicated the
surgical treatment (indicating that the tumour was in-
curable under those specific circumstances). The use of
imatinib as a neoadjuvant treatment offers the possibility
of a partial tumour regression and stabilisation of the
disease [9]. In general, the best therapeutic results have
been obtained in tumours with KIT mutations in exons
11 (85%) and 9 (45%) [3], although a global response rate
of only 40% in inoperable tumours indicates that resec-
tion is a non-curative procedure in many cases [17].
In our study, neoadjuvant therapy with imatinib did
not substantially reduce the tumour size, and histolo-
gically, we only observed extensive haemorrhagic foci
without a decrease in the number of tumour cells or
the presence of myxohyaline stroma, necrosis, or cys-
tic degeneration, as previously described in cases that
exhibited an initial response to treatment [3]. How-
ever, both tumours were completely resected, and after 8
months of postoperative follow-up and adjuvant therapy
with imatinib, the patient remains asymptomatic and
cancer-free.
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